Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Profile

Martin Cannon

Concepts (300)

Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Ovarian Neoplasms
23
2023
455
3.530
 Why?
Dendritic Cells
26
2023
132
3.530
 Why?
Cancer Vaccines
13
2020
78
2.820
 Why?
Immunotherapy
13
2025
251
1.860
 Why?
Th17 Cells
3
2020
26
1.410
 Why?
Antigens, Neoplasm
11
2019
145
1.250
 Why?
CD4-Positive T-Lymphocytes
8
2023
165
1.010
 Why?
Uterine Cervical Neoplasms
13
2011
299
0.890
 Why?
Oncogene Proteins, Viral
7
2011
52
0.760
 Why?
Neoplasm Recurrence, Local
3
2020
639
0.720
 Why?
T-Lymphocytes, Regulatory
6
2011
81
0.680
 Why?
T-Lymphocytes, Cytotoxic
12
2013
64
0.660
 Why?
Lymphocytes, Tumor-Infiltrating
5
2025
86
0.630
 Why?
Indoleamine-Pyrrole 2,3,-Dioxygenase
3
2014
16
0.620
 Why?
CD8-Positive T-Lymphocytes
12
2025
140
0.580
 Why?
Neoplasms
4
2019
1314
0.530
 Why?
Antibodies, Monoclonal
5
2019
475
0.530
 Why?
DNA-Binding Proteins
5
2007
423
0.520
 Why?
Interleukin-17
2
2020
34
0.510
 Why?
p38 Mitogen-Activated Protein Kinases
2
2014
94
0.490
 Why?
T-Lymphocytes
5
2017
318
0.430
 Why?
Ascites
1
2014
32
0.420
 Why?
Immunologic Surveillance
2
2011
10
0.410
 Why?
Cytokines
4
2014
622
0.380
 Why?
Signal Transduction
3
2017
1724
0.380
 Why?
Female
42
2023
28277
0.380
 Why?
Carcinoma
2
2017
135
0.370
 Why?
T-Lymphocytes, Helper-Inducer
2
2011
39
0.360
 Why?
Carcinoma, Hepatocellular
2
2025
208
0.360
 Why?
Immunotherapy, Active
1
2011
4
0.360
 Why?
Humans
54
2025
52441
0.350
 Why?
Serine Endopeptidases
3
2009
50
0.350
 Why?
Cytotoxicity, Immunologic
7
2011
55
0.350
 Why?
Liver Neoplasms
2
2025
341
0.330
 Why?
Adoptive Transfer
1
2009
30
0.310
 Why?
Immunotherapy, Adoptive
3
2005
156
0.300
 Why?
Cell Line, Tumor
14
2025
1429
0.290
 Why?
Interferon-gamma
7
2020
169
0.290
 Why?
Epitopes, T-Lymphocyte
3
2008
25
0.280
 Why?
Tumor Microenvironment
3
2025
257
0.280
 Why?
Lymphocyte Activation
3
2005
161
0.260
 Why?
Animals
17
2025
13485
0.260
 Why?
Adjuvants, Immunologic
3
2011
51
0.260
 Why?
Papillomavirus Vaccines
1
2007
69
0.250
 Why?
Herpesvirus 4, Human
2
2005
43
0.250
 Why?
Immunodominant Epitopes
2
2008
9
0.250
 Why?
Dependovirus
3
2011
104
0.220
 Why?
HLA-A2 Antigen
3
2009
11
0.210
 Why?
Cell Transformation, Viral
1
2003
25
0.200
 Why?
Cell Line, Transformed
1
2003
74
0.200
 Why?
Poxviridae Infections
1
2022
4
0.190
 Why?
Oncolytic Virotherapy
1
2022
19
0.190
 Why?
Programmed Cell Death 1 Receptor
2
2025
46
0.190
 Why?
Poxviridae
1
2022
7
0.190
 Why?
Myxoma virus
1
2022
14
0.190
 Why?
Interferon Type I
1
2022
28
0.190
 Why?
Mice
10
2025
5899
0.190
 Why?
Cystadenocarcinoma, Serous
5
2009
73
0.190
 Why?
Vaccination
4
2010
294
0.180
 Why?
Disease-Free Survival
2
2020
461
0.180
 Why?
Papillomavirus E7 Proteins
5
2011
30
0.180
 Why?
Interleukin-10
2
2017
81
0.180
 Why?
Receptor, erbB-2
4
2008
79
0.180
 Why?
Genes, MHC Class I
3
2008
11
0.180
 Why?
Flow Cytometry
8
2013
396
0.180
 Why?
Injections, Intradermal
1
2020
14
0.170
 Why?
Macrophages
4
2022
357
0.170
 Why?
Membrane Proteins
4
2011
344
0.170
 Why?
Testis
2
2011
74
0.170
 Why?
Immunity, Humoral
1
2020
23
0.170
 Why?
Coculture Techniques
3
2014
142
0.170
 Why?
Folate Receptor 1
1
2020
27
0.160
 Why?
Cell Movement
2
2019
271
0.160
 Why?
Enzyme-Linked Immunosorbent Assay
2
2013
234
0.160
 Why?
Carcinoma, Lewis Lung
1
2019
10
0.160
 Why?
B-Lymphocytes
5
2017
178
0.160
 Why?
Repressor Proteins
3
2011
150
0.150
 Why?
Melanoma, Experimental
1
2019
34
0.150
 Why?
Self Tolerance
1
2019
1
0.150
 Why?
Costimulatory and Inhibitory T-Cell Receptors
1
2019
1
0.150
 Why?
Transplantation, Autologous
1
2020
479
0.150
 Why?
Aged
12
2020
10242
0.140
 Why?
Cells, Cultured
6
2014
1583
0.140
 Why?
Cytotoxicity Tests, Immunologic
4
2005
26
0.140
 Why?
Mice, Inbred C57BL
4
2025
1888
0.140
 Why?
N-Acetylglucosaminyltransferases
1
2017
14
0.140
 Why?
Receptors, Notch
1
2017
26
0.130
 Why?
HLA Antigens
4
2006
55
0.130
 Why?
Middle Aged
16
2020
13133
0.130
 Why?
Human Umbilical Vein Endothelial Cells
2
2014
102
0.130
 Why?
Neoplastic Stem Cells
1
2017
88
0.130
 Why?
Carcinoma, Papillary
3
2005
49
0.120
 Why?
Poliovirus Vaccine, Oral
2
2005
4
0.120
 Why?
Genetic Vectors
3
2011
128
0.120
 Why?
Poliovirus
2
2005
10
0.110
 Why?
Neoplasm Proteins
1
2017
328
0.110
 Why?
Adult
15
2011
14205
0.110
 Why?
Clinical Trials, Phase I as Topic
1
2015
24
0.110
 Why?
Adenocarcinoma
3
2004
403
0.110
 Why?
Galectin 3
1
2014
13
0.110
 Why?
Antigen Presentation
5
2009
25
0.110
 Why?
Kallikreins
2
2005
19
0.110
 Why?
Neoplasm Invasiveness
3
2017
278
0.110
 Why?
Cystadenocarcinoma, Papillary
2
2005
14
0.110
 Why?
Histocompatibility Antigens Class I
2
2005
47
0.110
 Why?
Peptide Fragments
4
2009
214
0.100
 Why?
Endometrial Neoplasms
2
2005
144
0.100
 Why?
Uterine Neoplasms
2
2005
57
0.100
 Why?
Papillomavirus Infections
3
2011
170
0.100
 Why?
Mutation
1
2019
1331
0.100
 Why?
Intracellular Signaling Peptides and Proteins
2
2022
141
0.090
 Why?
Lymphocytes
1
2013
146
0.090
 Why?
Antigens, Viral
3
2007
44
0.090
 Why?
Killer Cells, Natural
4
2005
111
0.090
 Why?
V-Set Domain-Containing T-Cell Activation Inhibitor 1
1
2011
4
0.090
 Why?
rho GTP-Binding Proteins
1
2011
8
0.090
 Why?
Clonal Anergy
1
2011
13
0.090
 Why?
Disease Models, Animal
3
2025
1483
0.090
 Why?
A Kinase Anchor Proteins
1
2011
3
0.090
 Why?
Calmodulin-Binding Proteins
1
2011
10
0.090
 Why?
Antigen-Presenting Cells
1
2011
22
0.090
 Why?
Antigens, Surface
1
2011
37
0.090
 Why?
Human papillomavirus 16
1
2011
44
0.090
 Why?
Antineoplastic Agents, Alkylating
1
2011
78
0.090
 Why?
Immunity, Cellular
2
2008
64
0.090
 Why?
Drug Resistance, Neoplasm
5
2017
336
0.090
 Why?
Uterine Cervical Dysplasia
1
2011
51
0.090
 Why?
Cyclophosphamide
1
2011
176
0.080
 Why?
Prostate
1
2011
116
0.080
 Why?
Imidazoles
1
2011
114
0.080
 Why?
Diphosphonates
1
2011
92
0.080
 Why?
Gene Expression Regulation, Neoplastic
4
2011
853
0.080
 Why?
Phenotype
1
2013
792
0.080
 Why?
Papillomaviridae
3
2005
102
0.080
 Why?
Neoplasm Staging
3
2007
768
0.080
 Why?
Gene Expression Profiling
2
2005
1099
0.080
 Why?
K562 Cells
2
2008
41
0.080
 Why?
Carrier Proteins
1
2011
312
0.080
 Why?
CA-125 Antigen
1
2008
16
0.070
 Why?
Immediate-Early Proteins
1
2008
19
0.070
 Why?
Cytomegalovirus
1
2008
32
0.070
 Why?
Green Fluorescent Proteins
1
2008
85
0.070
 Why?
RNA, Messenger
4
2005
1134
0.070
 Why?
Interleukin-4
2
2005
41
0.070
 Why?
Antibody Formation
1
2007
51
0.070
 Why?
Prostatic Neoplasms
1
2011
398
0.070
 Why?
Antibodies, Viral
1
2007
113
0.070
 Why?
Amino Acid Sequence
2
2005
576
0.070
 Why?
RNA Interference
2
2017
183
0.070
 Why?
Molecular Sequence Data
2
2005
778
0.060
 Why?
Ovary
3
2017
101
0.060
 Why?
Oligonucleotide Array Sequence Analysis
2
2005
412
0.060
 Why?
Recombinant Proteins
1
2007
490
0.060
 Why?
Breast Neoplasms
3
2003
1203
0.060
 Why?
Hypersensitivity, Delayed
1
2005
18
0.060
 Why?
Monocytes
2
2022
124
0.060
 Why?
CTLA-4 Antigen
1
2025
32
0.060
 Why?
Neoplasms, Squamous Cell
1
2005
7
0.060
 Why?
Cell Line
4
2010
1020
0.060
 Why?
Electroporation
1
2005
18
0.060
 Why?
Poliomyelitis
1
2005
5
0.060
 Why?
Enterotoxins
1
2005
12
0.060
 Why?
Gene Transfer Techniques
1
2005
44
0.060
 Why?
Reverse Transcriptase Polymerase Chain Reaction
4
2008
580
0.060
 Why?
Interleukin-12
1
2005
26
0.060
 Why?
Genes, erbB-2
1
2005
8
0.060
 Why?
Immunologic Memory
1
2005
31
0.060
 Why?
Antigens, Heterophile
1
2005
1
0.060
 Why?
Plasmodium falciparum
1
2005
23
0.060
 Why?
Burkitt Lymphoma
1
2005
27
0.060
 Why?
Endemic Diseases
1
2005
26
0.060
 Why?
Epstein-Barr Virus Infections
1
2005
31
0.060
 Why?
Malaria, Falciparum
1
2005
21
0.060
 Why?
Gangliosides
1
2004
4
0.050
 Why?
Ascitic Fluid
1
2004
13
0.050
 Why?
Proteins
2
2005
353
0.050
 Why?
Genetic Therapy
1
2005
127
0.050
 Why?
Ovariectomy
1
2004
115
0.050
 Why?
Vaccines, Subunit
1
2004
15
0.050
 Why?
Hysterectomy
1
2004
90
0.050
 Why?
Immunization, Passive
1
2004
28
0.050
 Why?
Clinical Trials as Topic
2
2007
461
0.050
 Why?
Interleukin-6
1
2005
271
0.050
 Why?
Tumor Necrosis Factor-alpha
2
2019
390
0.050
 Why?
Cell Differentiation
2
2004
667
0.050
 Why?
Protein Binding
1
2005
673
0.050
 Why?
Epithelial Cells
1
2005
217
0.050
 Why?
Vesiculovirus
1
2022
6
0.050
 Why?
Virus Latency
1
2003
53
0.050
 Why?
Vaccinia virus
1
2022
6
0.050
 Why?
Host Specificity
1
2022
5
0.050
 Why?
Cell Adhesion Molecules
1
2003
89
0.050
 Why?
Cell Communication
1
2003
74
0.050
 Why?
Nucleotidyltransferases
1
2022
16
0.050
 Why?
Mammals
1
2022
59
0.050
 Why?
Tumor Cells, Cultured
4
2003
441
0.050
 Why?
Xenograft Model Antitumor Assays
2
2017
218
0.050
 Why?
Rabbits
1
2022
370
0.050
 Why?
Blood Transfusion
1
2002
126
0.050
 Why?
Radiotherapy
1
2002
128
0.050
 Why?
Down-Regulation
1
2003
348
0.050
 Why?
Disease Progression
2
2019
870
0.050
 Why?
Viral Proteins
1
2022
164
0.040
 Why?
Immunohistochemistry
4
2005
977
0.040
 Why?
Carcinoma, Squamous Cell
1
2004
331
0.040
 Why?
Transcriptome
1
2022
357
0.040
 Why?
Endothelium
1
2019
38
0.040
 Why?
Intercellular Adhesion Molecule-1
1
2019
59
0.040
 Why?
Gene Expression
3
2008
618
0.040
 Why?
Antineoplastic Combined Chemotherapy Protocols
1
2004
1020
0.040
 Why?
Injections, Intraperitoneal
2
2010
55
0.030
 Why?
Tissue Banks
1
2017
9
0.030
 Why?
Antibodies, Monoclonal, Humanized
3
2004
230
0.030
 Why?
Mice, Inbred NOD
1
2017
91
0.030
 Why?
STAT3 Transcription Factor
1
2017
89
0.030
 Why?
Glycosylation
1
2017
104
0.030
 Why?
Tumor Burden
1
2017
132
0.030
 Why?
RNA, Small Interfering
1
2017
217
0.030
 Why?
Multiple Myeloma
1
2011
3013
0.030
 Why?
Protein Processing, Post-Translational
1
2017
152
0.030
 Why?
Kaplan-Meier Estimate
1
2017
485
0.030
 Why?
Lung Neoplasms
1
2002
643
0.030
 Why?
Survival Analysis
2
2010
656
0.030
 Why?
Apoptosis
2
2014
1120
0.030
 Why?
Perforin
2
2005
12
0.030
 Why?
Pore Forming Cytotoxic Proteins
2
2005
11
0.030
 Why?
Neovascularization, Pathologic
1
2014
158
0.030
 Why?
Anti-Bacterial Agents
1
2019
816
0.030
 Why?
Interleukin-2
2
2003
69
0.020
 Why?
Membrane Glycoproteins
2
2005
239
0.020
 Why?
Vaginal Smears
1
2011
28
0.020
 Why?
Organ Specificity
1
2011
116
0.020
 Why?
Prostate-Specific Antigen
1
2011
41
0.020
 Why?
DNA, Viral
1
2011
134
0.020
 Why?
Time Factors
2
2010
2987
0.020
 Why?
Major Histocompatibility Complex
1
2010
13
0.020
 Why?
Prognosis
2
2005
2100
0.020
 Why?
Transduction, Genetic
1
2008
44
0.020
 Why?
Fluorescent Antibody Technique
1
2008
110
0.020
 Why?
Leukocytes, Mononuclear
1
2008
122
0.020
 Why?
Alphapapillomavirus
1
2007
13
0.020
 Why?
T-Lymphocyte Subsets
1
2007
40
0.020
 Why?
Models, Immunological
1
2007
8
0.020
 Why?
Aged, 80 and over
2
2005
3449
0.020
 Why?
Immune Tolerance
1
2007
91
0.020
 Why?
Adolescent
2
2011
6713
0.020
 Why?
HLA-B Antigens
1
2006
8
0.020
 Why?
Clone Cells
1
2006
76
0.020
 Why?
Immunity, Innate
1
2007
109
0.020
 Why?
Male
3
2011
26874
0.010
 Why?
Combined Modality Therapy
1
2007
641
0.010
 Why?
Claudin-3
1
2005
5
0.010
 Why?
Claudin-4
1
2005
7
0.010
 Why?
Mice, Inbred C3H
1
2005
80
0.010
 Why?
Protein Sorting Signals
1
2005
7
0.010
 Why?
Peptides
1
2006
239
0.010
 Why?
Protein Engineering
1
2005
18
0.010
 Why?
Histocompatibility Antigens Class II
1
2005
35
0.010
 Why?
Mice, SCID
1
2005
178
0.010
 Why?
Plasmids
1
2005
162
0.010
 Why?
Species Specificity
1
2005
194
0.010
 Why?
Protein Folding
1
2005
60
0.010
 Why?
Epithelium
1
2004
65
0.010
 Why?
Endocytosis
1
2005
52
0.010
 Why?
Receptors, Cell Surface
1
2005
111
0.010
 Why?
Carboplatin
1
2004
55
0.010
 Why?
Radiotherapy, Adjuvant
1
2004
65
0.010
 Why?
Transfection
1
2005
365
0.010
 Why?
Polymerase Chain Reaction
1
2005
458
0.010
 Why?
Paclitaxel
1
2004
91
0.010
 Why?
Antineoplastic Agents, Hormonal
1
2004
56
0.010
 Why?
Antibody-Dependent Cell Cytotoxicity
1
2003
11
0.010
 Why?
Tumor Stem Cell Assay
1
2003
16
0.010
 Why?
Proportional Hazards Models
1
2005
446
0.010
 Why?
Cervix Uteri
1
2004
49
0.010
 Why?
Up-Regulation
1
2005
462
0.010
 Why?
Swine
1
2005
428
0.010
 Why?
Kinetics
1
2005
613
0.010
 Why?
Keratinocytes
1
2004
91
0.010
 Why?
Leukocytes
1
2003
54
0.010
 Why?
Receptors, Interleukin-2
1
2002
6
0.010
 Why?
Lymphocyte Subsets
1
2002
14
0.010
 Why?
Receptors, Antigen, T-Cell
1
2003
48
0.010
 Why?
Cell Culture Techniques
1
2003
97
0.010
 Why?
Antigens, CD19
1
2002
27
0.010
 Why?
Receptors, IgG
1
2002
22
0.010
 Why?
Cell Death
1
2003
169
0.010
 Why?
Doxorubicin
1
2004
246
0.010
 Why?
Cisplatin
1
2004
282
0.010
 Why?
Immunophenotyping
1
2002
115
0.010
 Why?
Survival Rate
1
2005
944
0.010
 Why?
Antibodies, Monoclonal, Murine-Derived
1
2002
46
0.010
 Why?
Tumor Virus Infections
1
2002
47
0.010
 Why?
Fatal Outcome
1
2002
193
0.010
 Why?
Young Adult
1
2011
4346
0.010
 Why?
Cell Division
1
2002
288
0.010
 Why?
Case-Control Studies
1
2004
1202
0.010
 Why?
Prospective Studies
1
2004
2433
0.010
 Why?
Risk Factors
1
2004
3971
0.010
 Why?
Antineoplastic Agents
1
2002
1216
0.010
 Why?
Cannon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (300) concept(s)
_
Co-Authors Expand Description
See all (21) people
_
Similar People Expand Description
See all (33) people
_
Same Department Expand Description
Search Department